Skip to main content

Specimen Collection Manual and Test Catalog

  or
  or
  or

SERUM FREE LIGHT CHAINS

Geisinger Epic Procedure Code:  LAB2567    Geisinger Epic ID:  15049

SPECIMEN COLLECTION
Specimen type: 

Serum


Preferred collection container: 
Specimen required: 

2 mL aliquot serum; minimum 0.5 mL.



SPECIMEN PROCESSING
Processing instructions: 

Allow serum to clot. Centrifuge to separate serum within 2 hours of collection.


Transport temperature: 

Refrigerated.


Specimen stability: 

Refrigerated: 3 weeks. Frozen: 3 months.


Rejection criteria: 

Stability limits exceeded.



TEST DETAILS
Reference interval: 

Kappa FLC: 3.30-19.40 mg/L.
Lambda FLC: 5.71-26.30 mg/L
Kappa/Lambda FLC Ratio: 0.26-1.65.


Additional information: 

Decreased kidney function can cause an increase in serum Kappa and Lambda Free Light Chains, and Free Light Chain Ratio. For individuals with decreased kidney function, the following reference intervals apply:

Kappa FLC: eGFR 45-59: 7.8-83.6 mg/L 
                    eGFR 30-44: 8.8-103.3 mg/L 
                    eGFR <30: 11.7-265.1 mg/L

Lambda FLC: eGFR 45-59: 7.3-65.1 mg/L
                       eGFR 30-44: 8.2-73.2 mg/L 
                       eGFR <30: 12.6-150.9 mg/L

Kappa/Lambda FLC Ratio: eGFR 45-59: 0.46-2.62 
                                            eGFR 30-44: 0.48-3.38 
                                            eGFR <30: 0.54-3.30


CPT code(s):  83521 x 2
Note: The billing party has sole responsibility for CPT coding.  Any questions regarding coding should be directed to the payer being billed.
The CPT codes provided by GML are based on AMA guidelines and are for informational purposes only.

Test includes: 

Kappa FLC, Lambda FLC, Kappa/Lambda FLC Ratio.


Methodology: 
Immunoturbidity
Synonyms: 

Kappa Lambda Serum; Free Light chains, KLS


Clinical significance: 

Measurement of the various amounts of the different types of light chain aids in the diagnosis and monitoring of multiple myleoma, lymphocyte neoplasm, Waldenstrom's macroglobulinemia and connective tissues diseases such as systemic lupus erythematosus.


Doctoral Director(s): 
Hoi-Ying Elsie Yu, PhD, DABCC, FADLM
Sheng-Ying (Margaret) Lo, PhD, DABCC
Review Date:  12/17/2024

Performing Locations